<博士論文>
NSAIDs起因性小腸粘膜傷害に対するPPIの作用と薬剤代謝酵素遺伝子多型との関連の検討

作成者
論文調査委員
本文言語
学位授与年度
学位授与大学
学位
学位種別
アクセス権
関連DOI
概要 BACKGROUND:Simultaneous use of proton pump inhibitors (PPIs) has been shown to increase the risk of nonsteroidal anti-inflammatory drug (NSAID)-induced small bowel injury.
AIM:To investigate whether po...lymorphisms of the cytochrome P450 2C19 gene (CYP2C19), encoding a key metabolising enzyme for PPIs, are associated with small bowel injury induced by celecoxib in combination with the PPI rabeprazole.
METHODS:Study participants included 55 healthy Japanese volunteers, who participated in the PPI-NSAID Kyushu University Study using video capsule endoscopy. For 2 weeks, 26 subjects were treated with celecoxib plus rabeprazole (rabeprazole group), and 29 subjects received celecoxib plus placebo (placebo group). All subjects were genotyped for CYP2C19 using real-time fluorescent polymerase chain reaction. Subjects were sub-classified as poor metabolizers or extensive metabolizers. The incidence and number of small bowel injuries were compared between poor metabolizers and extensive metabolizers in each group.
RESULTS:In the rabeprazole group, the incidence of small bowel injuries was significantly higher in poor metabolizers than in extensive metabolizers (85.7% vs 31.6%, P=.026). The number of mucosal injuries in the rabeprazole group was also significantly higher in poor metabolizers compared with extensive metabolizers (median [range] 3 [0-31] vs 0 [0-7], P=.01). In addition, we found a significant interaction between CYP2C19 genotype and concomitant use of rabeprazole in subjects at risk for celecoxib-induced small bowel injury.
CONCLUSIONS:The CYP2C19 genotype might be associated with the risk of small bowel injury when celecoxib is combined with rabeprazole.
続きを見る

本文ファイル

pdf med3134_abstract pdf 108 KB 464 要旨
pdf med3134_summary pdf 108 KB 177 要約
pdf med3134_review pdf 171 KB 215 審査結果要旨

詳細

レコードID
査読有無
権利関係
関連PubMed ID
報告番号
学位記番号
授与日(学位/助成/特許)
受理日
部局
登録日 2018.05.30
更新日 2018.08.31

この資料を見た人はこんな資料も見ています